Please assess the completion status of the following clinical trial:

Trial Title: Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Screening:~* As of protocol Version 2 there is no screening phase.Patients previously consented to the screening phase could still be eligible for treatment if consented for treatment, based upon the updated eligibility criteria.~Treatment:~* Patients with histologically confirmed Multiple Myeloma that are being considered for high dose chemotherapy and autologous stem cell transplant.~* Patients must have a bone marrow biopsy available, or one scheduled to be performed for a clinical indication so that survivin expression could be determined (note: survivin staining in tumor need not be resulted prior to enrollment or treatment as it is obtained for correlative science).~* Patients planned for treatment with high dose melphalan and autologous hematopoietic cell transplant (HCT).~* Complete blood count (CBC) with an absolute neutrophil count (ANC) \>= 1,000/uL, hemoglobin \>= 8.0 g/dL and platelet count \>= 50,000/uL.~* Liver enzymes: total bilirubin less than or equal to 2 mg/dL (\>2 mg/dL permitted if the patient has evidence of Gilbert's disease based upon prior bilirubin elevation or genetic testing); Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) less than 1.5 X the upper limit of normal (ULN).~* Signed informed consent form in accordance with institutional and federal law policies.~Exclusion Criteria:~Treatment:~* Patients with Complete Response (CR) or stringent CR after induction therapy as defined by International Response Criteria after most recent therapy.~* Patients with progressive disease at time of transplant.~* Pregnant or lactating woman (as evaluated by serum testing within 48 hours of administration of the first vaccine in women of child bearing potential).~* HIV infection confirmed by nucleic acid tests (NAT).~* Common variable immunodeficiency.~* Active central nervous system (CNS) malignancy.~* Active bacterial, fungal or viral infection.~* Prior history of allogeneic hematopoietic cell transplantation~* Prior malignancy within 5 years of enrollment excluding non-melanoma skin cancer or cervical carcinoma after curative resection, not requiring chemotherapy.~* History of severe allergy (e.g., anaphylaxis) to any component of Prevnar or any diphtheria-toxoid containing vaccine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Survivin Vaccine and Autologous HCT (Type: EXPERIMENTAL): Dendritic Cell Survivin Vaccine (DC:AdmS) and Autologous Hematopoietic Cell Transplantation (HCT). Participants will receive 1 pre-transplant survivin vaccine, 7-30 days prior to stem cell apheresis collection. After the first survivin vaccination, participants will be mobilized with Granulocyte-colony Stimulating Factor (G-CSF). A second survivin vaccine will be administered on day +21 (between day+20 and +34) after HCT. All participants will be co-immunized with Prevnar 13 at each time they receive the survivin vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).